Oral l-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease
l-Arginine is the physiological substrate for nitric oxide synthesis by the vascular endothelium. In hypercholesterolaemic rabbits, oral l-arginine reduces atheroma, improves endothelium-dependent dilatation and reduces monocyte/endothelial cell adhesion. The effect of oral l-arginine on endothelial...
Gespeichert in:
| Veröffentlicht in: | Atherosclerosis 1997-03, Vol.129 (2), p.261-269 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 269 |
|---|---|
| container_issue | 2 |
| container_start_page | 261 |
| container_title | Atherosclerosis |
| container_volume | 129 |
| creator | Adams, Mark R McCredie, Robyn Jessup, Wendy Robinson, Jacqui Sullivan, David Celermajer, David S |
| description | l-Arginine is the physiological substrate for nitric oxide synthesis by the vascular endothelium. In hypercholesterolaemic rabbits, oral
l-arginine reduces atheroma, improves endothelium-dependent dilatation and reduces monocyte/endothelial cell adhesion. The effect of oral
l-arginine on endothelial physiology is unknown, however, in humans with established atherosclerosis. In a prospective, double-blind, randomised crossover trial, ten men aged 41±2 years with angiographically proven coronary atherosclerosis took
l-arginine (7 g three times per day) or placebo for 3 days each, with a washout period of 10 days. After
l-arginine, compared to placebo, plasma levels of arginine were increased (318±18 vs. 124±9
μmol/l,
P |
| doi_str_mv | 10.1016/S0021-9150(96)06044-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78964336</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021915096060443</els_id><sourcerecordid>78964336</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-34cd1818c55fa63bd6dcbe967f1d98619a2151d0bef41a627ebbc952291d2e463</originalsourceid><addsrcrecordid>eNqFkc9u1DAQxi0EKkvhESp8QKgcArZje-NTharyR6rUQ-nZcuzJrlFiL7ZTtC_C8-J0V8uR08j6fjPzeT6ELij5SAmVn-4JYbRRVJBLJT8QSThv2mdoRbu1aijv-HO0OiEv0aucfxJC-Jp2Z-hMUSKEVCv05y6ZEY-NSRsffADsp12Kj5AxBBfLFkY_T42DXX1CKNj50RRTfAzYBIcTuNlWeIoh2n0BbNwW8qKW-G9C3WBhHDP2Ae_jHDZ4goB_-7LFNqYYTNpjkwrU4nwGk-E1ejGYMcObYz1HD19uflx_a27vvn6__nzbWC5FaVpuHe1oZ4UYjGx7J53tQcn1QJ3qJFWGUUEd6WHg1Ei2hr63SjCmqGPAZXuO3h_m1k__miEXPfm8eDUB4pz1ulOSt-0CigNoU8w5waB3yU_VuKZEL3nopzz0cmytpH7KQ7e17-K4YO4ncKeuYwBVf3fUTbZmHJIJ1ucTxmRLOrasf3vABhO12aSKPNwzQlvCOskEYZW4OhBQz_XoIelsPQQLziewRbvo_2P1L0hAtAg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78964336</pqid></control><display><type>article</type><title>Oral l-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Adams, Mark R ; McCredie, Robyn ; Jessup, Wendy ; Robinson, Jacqui ; Sullivan, David ; Celermajer, David S</creator><creatorcontrib>Adams, Mark R ; McCredie, Robyn ; Jessup, Wendy ; Robinson, Jacqui ; Sullivan, David ; Celermajer, David S</creatorcontrib><description>l-Arginine is the physiological substrate for nitric oxide synthesis by the vascular endothelium. In hypercholesterolaemic rabbits, oral
l-arginine reduces atheroma, improves endothelium-dependent dilatation and reduces monocyte/endothelial cell adhesion. The effect of oral
l-arginine on endothelial physiology is unknown, however, in humans with established atherosclerosis. In a prospective, double-blind, randomised crossover trial, ten men aged 41±2 years with angiographically proven coronary atherosclerosis took
l-arginine (7 g three times per day) or placebo for 3 days each, with a washout period of 10 days. After
l-arginine, compared to placebo, plasma levels of arginine were increased (318±18 vs. 124±9
μmol/l,
P<0.01) and endothelium-dependent dilatation of the brachial artery (measured as the change in diameter in resonse to reactive hyperaemia, using external vascular ultrasound) was improved (4.7±1.1 vs. 1.8±0.7%,
P<0.04). No changes were seen in endothelium-independent dilatation of the brachial artery (measured as the change in diameter in response to sublingual nitroglycerine), blood pressure, heart rate or fasting lipid levels. Serum from six of the ten subjects after
l-arginine and placebo was then added to confluent monolayers of human umbilical vein endothelial cells for 24 h, before human monocytes obtained by countercurrent centrifiguation elutriation were added and cell adhesion assessed by light microscopy. Adhesion was reduced following
l-arginine compared to placebo (42±2 vs. 50±1%,
P<0.01). In young men with coronary artery disease, oral
l-arginine improves endothelium-dependent dilatation and reduces monocyte/endothelial cell adhesion.</description><identifier>ISSN: 0021-9150</identifier><identifier>EISSN: 1879-1484</identifier><identifier>DOI: 10.1016/S0021-9150(96)06044-3</identifier><identifier>PMID: 9105569</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ireland Ltd</publisher><subject>Administration, Oral ; Adult ; Arginine - administration & dosage ; Arginine - pharmacokinetics ; Arginine - pharmacology ; Arginine - therapeutic use ; Atherosclerosis ; Biological and medical sciences ; Blood Proteins - chemistry ; Brachial Artery - drug effects ; Cell Adhesion - drug effects ; Cells, Cultured ; Coronary Artery Disease - blood ; Coronary Artery Disease - drug therapy ; Coronary Artery Disease - pathology ; Cross-Over Studies ; dietary supplements ; Double-Blind Method ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - metabolism ; Endothelium, Vascular - physiology ; General and cellular metabolism. Vitamins ; Hemodynamics - drug effects ; Humans ; Leukocytes ; Lipids - blood ; Male ; Medical sciences ; Monocytes - cytology ; Monocytes - drug effects ; Nitric oxide ; Nitric Oxide - biosynthesis ; Pharmacology. Drug treatments ; Prospective Studies ; Umbilical Veins ; Vasodilation - drug effects</subject><ispartof>Atherosclerosis, 1997-03, Vol.129 (2), p.261-269</ispartof><rights>1997 Elsevier Science Ireland Ltd</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-34cd1818c55fa63bd6dcbe967f1d98619a2151d0bef41a627ebbc952291d2e463</citedby><cites>FETCH-LOGICAL-c465t-34cd1818c55fa63bd6dcbe967f1d98619a2151d0bef41a627ebbc952291d2e463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0021915096060443$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2630826$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9105569$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adams, Mark R</creatorcontrib><creatorcontrib>McCredie, Robyn</creatorcontrib><creatorcontrib>Jessup, Wendy</creatorcontrib><creatorcontrib>Robinson, Jacqui</creatorcontrib><creatorcontrib>Sullivan, David</creatorcontrib><creatorcontrib>Celermajer, David S</creatorcontrib><title>Oral l-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease</title><title>Atherosclerosis</title><addtitle>Atherosclerosis</addtitle><description>l-Arginine is the physiological substrate for nitric oxide synthesis by the vascular endothelium. In hypercholesterolaemic rabbits, oral
l-arginine reduces atheroma, improves endothelium-dependent dilatation and reduces monocyte/endothelial cell adhesion. The effect of oral
l-arginine on endothelial physiology is unknown, however, in humans with established atherosclerosis. In a prospective, double-blind, randomised crossover trial, ten men aged 41±2 years with angiographically proven coronary atherosclerosis took
l-arginine (7 g three times per day) or placebo for 3 days each, with a washout period of 10 days. After
l-arginine, compared to placebo, plasma levels of arginine were increased (318±18 vs. 124±9
μmol/l,
P<0.01) and endothelium-dependent dilatation of the brachial artery (measured as the change in diameter in resonse to reactive hyperaemia, using external vascular ultrasound) was improved (4.7±1.1 vs. 1.8±0.7%,
P<0.04). No changes were seen in endothelium-independent dilatation of the brachial artery (measured as the change in diameter in response to sublingual nitroglycerine), blood pressure, heart rate or fasting lipid levels. Serum from six of the ten subjects after
l-arginine and placebo was then added to confluent monolayers of human umbilical vein endothelial cells for 24 h, before human monocytes obtained by countercurrent centrifiguation elutriation were added and cell adhesion assessed by light microscopy. Adhesion was reduced following
l-arginine compared to placebo (42±2 vs. 50±1%,
P<0.01). In young men with coronary artery disease, oral
l-arginine improves endothelium-dependent dilatation and reduces monocyte/endothelial cell adhesion.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Arginine - administration & dosage</subject><subject>Arginine - pharmacokinetics</subject><subject>Arginine - pharmacology</subject><subject>Arginine - therapeutic use</subject><subject>Atherosclerosis</subject><subject>Biological and medical sciences</subject><subject>Blood Proteins - chemistry</subject><subject>Brachial Artery - drug effects</subject><subject>Cell Adhesion - drug effects</subject><subject>Cells, Cultured</subject><subject>Coronary Artery Disease - blood</subject><subject>Coronary Artery Disease - drug therapy</subject><subject>Coronary Artery Disease - pathology</subject><subject>Cross-Over Studies</subject><subject>dietary supplements</subject><subject>Double-Blind Method</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - metabolism</subject><subject>Endothelium, Vascular - physiology</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>Leukocytes</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Monocytes - cytology</subject><subject>Monocytes - drug effects</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - biosynthesis</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Umbilical Veins</subject><subject>Vasodilation - drug effects</subject><issn>0021-9150</issn><issn>1879-1484</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9u1DAQxi0EKkvhESp8QKgcArZje-NTharyR6rUQ-nZcuzJrlFiL7ZTtC_C8-J0V8uR08j6fjPzeT6ELij5SAmVn-4JYbRRVJBLJT8QSThv2mdoRbu1aijv-HO0OiEv0aucfxJC-Jp2Z-hMUSKEVCv05y6ZEY-NSRsffADsp12Kj5AxBBfLFkY_T42DXX1CKNj50RRTfAzYBIcTuNlWeIoh2n0BbNwW8qKW-G9C3WBhHDP2Ae_jHDZ4goB_-7LFNqYYTNpjkwrU4nwGk-E1ejGYMcObYz1HD19uflx_a27vvn6__nzbWC5FaVpuHe1oZ4UYjGx7J53tQcn1QJ3qJFWGUUEd6WHg1Ei2hr63SjCmqGPAZXuO3h_m1k__miEXPfm8eDUB4pz1ulOSt-0CigNoU8w5waB3yU_VuKZEL3nopzz0cmytpH7KQ7e17-K4YO4ncKeuYwBVf3fUTbZmHJIJ1ucTxmRLOrasf3vABhO12aSKPNwzQlvCOskEYZW4OhBQz_XoIelsPQQLziewRbvo_2P1L0hAtAg</recordid><startdate>19970321</startdate><enddate>19970321</enddate><creator>Adams, Mark R</creator><creator>McCredie, Robyn</creator><creator>Jessup, Wendy</creator><creator>Robinson, Jacqui</creator><creator>Sullivan, David</creator><creator>Celermajer, David S</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970321</creationdate><title>Oral l-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease</title><author>Adams, Mark R ; McCredie, Robyn ; Jessup, Wendy ; Robinson, Jacqui ; Sullivan, David ; Celermajer, David S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-34cd1818c55fa63bd6dcbe967f1d98619a2151d0bef41a627ebbc952291d2e463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Arginine - administration & dosage</topic><topic>Arginine - pharmacokinetics</topic><topic>Arginine - pharmacology</topic><topic>Arginine - therapeutic use</topic><topic>Atherosclerosis</topic><topic>Biological and medical sciences</topic><topic>Blood Proteins - chemistry</topic><topic>Brachial Artery - drug effects</topic><topic>Cell Adhesion - drug effects</topic><topic>Cells, Cultured</topic><topic>Coronary Artery Disease - blood</topic><topic>Coronary Artery Disease - drug therapy</topic><topic>Coronary Artery Disease - pathology</topic><topic>Cross-Over Studies</topic><topic>dietary supplements</topic><topic>Double-Blind Method</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - metabolism</topic><topic>Endothelium, Vascular - physiology</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>Leukocytes</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Monocytes - cytology</topic><topic>Monocytes - drug effects</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - biosynthesis</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Umbilical Veins</topic><topic>Vasodilation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adams, Mark R</creatorcontrib><creatorcontrib>McCredie, Robyn</creatorcontrib><creatorcontrib>Jessup, Wendy</creatorcontrib><creatorcontrib>Robinson, Jacqui</creatorcontrib><creatorcontrib>Sullivan, David</creatorcontrib><creatorcontrib>Celermajer, David S</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Atherosclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adams, Mark R</au><au>McCredie, Robyn</au><au>Jessup, Wendy</au><au>Robinson, Jacqui</au><au>Sullivan, David</au><au>Celermajer, David S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral l-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease</atitle><jtitle>Atherosclerosis</jtitle><addtitle>Atherosclerosis</addtitle><date>1997-03-21</date><risdate>1997</risdate><volume>129</volume><issue>2</issue><spage>261</spage><epage>269</epage><pages>261-269</pages><issn>0021-9150</issn><eissn>1879-1484</eissn><abstract>l-Arginine is the physiological substrate for nitric oxide synthesis by the vascular endothelium. In hypercholesterolaemic rabbits, oral
l-arginine reduces atheroma, improves endothelium-dependent dilatation and reduces monocyte/endothelial cell adhesion. The effect of oral
l-arginine on endothelial physiology is unknown, however, in humans with established atherosclerosis. In a prospective, double-blind, randomised crossover trial, ten men aged 41±2 years with angiographically proven coronary atherosclerosis took
l-arginine (7 g three times per day) or placebo for 3 days each, with a washout period of 10 days. After
l-arginine, compared to placebo, plasma levels of arginine were increased (318±18 vs. 124±9
μmol/l,
P<0.01) and endothelium-dependent dilatation of the brachial artery (measured as the change in diameter in resonse to reactive hyperaemia, using external vascular ultrasound) was improved (4.7±1.1 vs. 1.8±0.7%,
P<0.04). No changes were seen in endothelium-independent dilatation of the brachial artery (measured as the change in diameter in response to sublingual nitroglycerine), blood pressure, heart rate or fasting lipid levels. Serum from six of the ten subjects after
l-arginine and placebo was then added to confluent monolayers of human umbilical vein endothelial cells for 24 h, before human monocytes obtained by countercurrent centrifiguation elutriation were added and cell adhesion assessed by light microscopy. Adhesion was reduced following
l-arginine compared to placebo (42±2 vs. 50±1%,
P<0.01). In young men with coronary artery disease, oral
l-arginine improves endothelium-dependent dilatation and reduces monocyte/endothelial cell adhesion.</abstract><cop>Amsterdam</cop><pub>Elsevier Ireland Ltd</pub><pmid>9105569</pmid><doi>10.1016/S0021-9150(96)06044-3</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9150 |
| ispartof | Atherosclerosis, 1997-03, Vol.129 (2), p.261-269 |
| issn | 0021-9150 1879-1484 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78964336 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Oral Adult Arginine - administration & dosage Arginine - pharmacokinetics Arginine - pharmacology Arginine - therapeutic use Atherosclerosis Biological and medical sciences Blood Proteins - chemistry Brachial Artery - drug effects Cell Adhesion - drug effects Cells, Cultured Coronary Artery Disease - blood Coronary Artery Disease - drug therapy Coronary Artery Disease - pathology Cross-Over Studies dietary supplements Double-Blind Method Endothelium, Vascular - drug effects Endothelium, Vascular - metabolism Endothelium, Vascular - physiology General and cellular metabolism. Vitamins Hemodynamics - drug effects Humans Leukocytes Lipids - blood Male Medical sciences Monocytes - cytology Monocytes - drug effects Nitric oxide Nitric Oxide - biosynthesis Pharmacology. Drug treatments Prospective Studies Umbilical Veins Vasodilation - drug effects |
| title | Oral l-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T08%3A26%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20l-arginine%20improves%20endothelium-dependent%20dilatation%20and%20reduces%20monocyte%20adhesion%20to%20endothelial%20cells%20in%20young%20men%20with%20coronary%20artery%20disease&rft.jtitle=Atherosclerosis&rft.au=Adams,%20Mark%20R&rft.date=1997-03-21&rft.volume=129&rft.issue=2&rft.spage=261&rft.epage=269&rft.pages=261-269&rft.issn=0021-9150&rft.eissn=1879-1484&rft_id=info:doi/10.1016/S0021-9150(96)06044-3&rft_dat=%3Cproquest_cross%3E78964336%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78964336&rft_id=info:pmid/9105569&rft_els_id=S0021915096060443&rfr_iscdi=true |